<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the healthy development of animal husbandry and human public health." exact="rift valley fever" post="vaccine virus-like particle immunogenicity cytokine fig-count: table-count: equation-count: ref-count:"/>
 <result pre="been developed worldwide (15), including Glaxo Smith Kline's Engerix (for" exact="hepatitis" post="B virus) and Cervarix (for human papillomavirus) as well"/>
 <result pre="(for human papillomavirus) as well as Merck's Recombivax HB (for" exact="hepatitis" post="B virus) and Gardasil (for human papillomavirus) (16). In"/>
 <result pre="(for human papillomavirus) (16). In 2011, the Hecoin vaccine for" exact="hepatitis" post="E virus (HEV) that was developed by Innovax Biotech"/>
 <result pre="countries. Dev Biol. (2003) 114:5–25. 10.1089/aid.2005.21.71414677673 5.FaburayBLaBeaudADMcVeyDSWilsonWCRichtJA. Current status of" exact="rift valley fever" post="vaccine development. Vaccines. (2017) 5:E29. 10.3390/vaccines503002928925970 6.IkegamiT. Molecular biology"/>
 <result pre="(2017) 5:E29. 10.3390/vaccines503002928925970 6.IkegamiT. Molecular biology and genetic diversity of" exact="rift valley fever" post="virus. Antivir Res. (2012) 95:293–310. 10.1016/j.antiviral.2012.06.00122710362 7.FaburayBWilsonWCGaudreaultNNDavisASShivannaVBawaBet al.. A"/>
 <result pre="virus. Antivir Res. (2012) 95:293–310. 10.1016/j.antiviral.2012.06.00122710362 7.FaburayBWilsonWCGaudreaultNNDavisASShivannaVBawaBet al.. A recombinant" exact="rift valley fever" post="virus glycoprotein subunit vaccine confers full protection against rift"/>
 <result pre="valley fever virus glycoprotein subunit vaccine confers full protection against" exact="rift valley fever" post="challenge in sheep. Scienti Rep. (2016) 6:27719. 10.1038/srep2771927296136 8.GopalRSchneemannA."/>
 <result pre="Biol. (2018) 1776:125–41. 10.1007/978-1-4939-7808-3_829869238 9.LiYTWangCLZhengXXWangHLZhaoYKGaiWWet al.. Development and characterization of" exact="rift valley fever" post="virus-like particles. Gene Mol Res. (2016) 15:1–13. 10.4238/gmr.1501777227050999 10.ZhaoYZhengXHeSLiYWangWGaiWet"/>
 <result pre="10.4238/gmr.1501777227050999 10.ZhaoYZhengXHeSLiYWangWGaiWet al.. Equine immunoglobulin F(ab')2 fragments protect mice from" exact="rift valley fever" post="virus infection. Int Immunopharmacol. (2018) 64:217–22. 10.1016/j.intimp.2018.09.00230199846 11.GoldbergALProtein degradation"/>
 <result pre="proteins. Nature. (2003) 426:895–9. 10.1038/nature0226314685250 12.PiperMESorensonDRGerrardSR. Efficient cellular release of" exact="rift valley fever" post="virus requires genomic RNA. PLoS ONE. (2011) 6:e18070. 10.1371/journal.pone.001807021445316"/>
 <result pre="RNA. PLoS ONE. (2011) 6:e18070. 10.1371/journal.pone.001807021445316 13.LiYZhaoYWangCZhengXWangHGaiWet al.. Packaging of" exact="rift valley fever" post="virus pseudoviruses and establishment of a neutralization assay method."/>
 <result pre="10.1016/j.vaccine.2012.10.08323142589 24.ZhangXWeiMPanHLinZWangKWengZet al.. Robust manufacturing and comprehensive characterization of recombinant" exact="hepatitis" post="E virus-like particles in hecolin(R). Vaccine. (2014) 32:4039–50. 10.1016/j.vaccine.2014.05.06424892250"/>
 <result pre="Rev Vacc. (2007) 6:381–90. 10.1586/14760584.6.3.38117542753 26.KortekaasJOreshkovaNCobos-JimenezVVloetRPPotgieterCAMoormannRJ. Creation of a nonspreading" exact="rift valley fever" post="virus. J Virol. (2011) 85:12622–30. 10.1128/JVI.00841-1121957302 27.HabjanMPenskiNWagnerVSpiegelMOverbyAKKochsGet al.. Efficient"/>
 <result pre="Vaccination with virus-like particles protects mice from lethal infection of" exact="rift valley fever" post="virus. Virology. (2009) 385:409–15. 10.1016/j.virol.2008.12.01219157482"/>
</results>
